The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 16, 2025
Filed:
Jul. 06, 2018
The Broad Institute, Inc., Cambridge, MA (US);
Massachusetts Institute of Technology, Cambridge, MA (US);
President and Fellows of Harvard College, Cambridge, MA (US);
Feng Zhang, Cambridge, MA (US);
Jonathan S. Gootenberg, Cambridge, MA (US);
Omar O. Abudayyeh, Cambridge, MA (US);
Pardis Sabeti, Cambridge, MA (US);
Cameron Myhrvold, Cambridge, MA (US);
Catherine Amanda Freije, Cambridge, MA (US);
THE BROAD INSTITUTE, INC., Cambridge, MA (US);
MASSACHUETTS INSTITUTE OF TECHNOLOGY, Cambridge, MA (US);
PRESIDENT AND FELLOWS OF HARVARD COLLEGE, Cambridge, NC (US);
Abstract
The present invention offers a new approach for highly multiplexed, programmable antiviral therapies that directly target viral RNA, and can be flexibly adapted to target novel viruses or emerging outbreak pathogens. Class 2, type VI CRISPR system-based therapies can be used in combination with existing antiviral compounds for viruses where such compounds exist, either by increasing their efficacy or by preventing the evolution of specific drug resistance mutations. Perhaps most excitingly, if a virus evolves resistance to a specific guide RNA sequence, it is easy to switch to a different guide RNA sequence, or to design a new guide sequence to target the new mutation. Such approaches should prevent the widespread development of resistance to Class 2, type VI CRISPR system-based therapies.